Education
About Us
Working with TipRanks
Follow Us
Nexalin Technology, Inc. (NXL)
:NXL
NXL Stock Chart & Stats
$1.08
-$0.26(-8.15%)
At close: 4:00 PM EST
$1.08
-$0.26(-8.15%)
Day’s Range― - ―
52-Week Range$0.70 - $3.87
Previous CloseN/A
Volume286.46K
Average Volume (3M)134.75K
Market Cap
$15.51M
Enterprise ValueN/A
Total Cash (Recent Filing)$4.35M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.16
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding18,651,940
10 Day Avg. Volume130,904
30 Day Avg. Volume134,751
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)6.92
Price to Sales (P/S)150.75
P/FCF Ratio-6.45
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$231.00K
Bulls Say, Bears Say
Bulls Say
Innovative TechnologyNexalin's innovative waveform technology has potential as a solution for treating Alzheimer's disease and other conditions, supporting the maintenance of a Buy rating.
Regulatory ApprovalNexalin Technology, Inc. is making progress in developing evidence for the efficacy of its neurostimulation technology, which is expected to support the regulatory approval process.
Bears Say
Financial PerformanceNXL reported a GAAP net loss per share wider than the estimate due mostly to higher than expected operating expenses.
Regulatory ChallengesThe regulatory pathway for Nexalin's products is taking slightly longer than expected, leading to a lowered revenue estimate and price target.
Nexalin Technology, Inc. News
NXL FAQ
What was Nexalin Technology, Inc.’s price range in the past 12 months?
Nexalin Technology, Inc. lowest stock price was $0.70 and its highest was $3.87 in the past 12 months.
What is Nexalin Technology, Inc.’s market cap?
Nexalin Technology, Inc.’s market cap is $15.51M.
When is Nexalin Technology, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nexalin Technology, Inc.’s earnings last quarter?
Currently, no data Available
Is Nexalin Technology, Inc. overvalued?
According to Wall Street analysts Nexalin Technology, Inc.’s price is currently Overvalued.
Does Nexalin Technology, Inc. pay dividends?
Nexalin Technology, Inc. does not currently pay dividends.
What is Nexalin Technology, Inc.’s EPS estimate?
Nexalin Technology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nexalin Technology, Inc. have?
Nexalin Technology, Inc. has 18,651,940 shares outstanding.
What happened to Nexalin Technology, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nexalin Technology, Inc.?
Currently, no hedge funds are holding shares in NXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nexalin Technology, Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
Technical Analysis
Co-Diagnostics
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Inspira Technologies Oxy BHN
―
Envoy Medical
―
Ownership Overview
22.31% Insiders
1.22% Mutual Funds
0.91% Other Institutional Investors
74.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---